{"id":102986,"date":"2026-05-25T02:19:42","date_gmt":"2026-05-25T02:19:42","guid":{"rendered":"https:\/\/flamenet.io\/2026\/05\/25\/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-cisplatin-ineligible-resectable-muscle\/"},"modified":"2026-05-25T02:19:42","modified_gmt":"2026-05-25T02:19:42","slug":"merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-cisplatin-ineligible-resectable-muscle","status":"publish","type":"post","link":"https:\/\/flamenet.io\/2026\/05\/25\/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-cisplatin-ineligible-resectable-muscle\/","title":{"rendered":"Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer &#8211; BioSpace"},"content":{"rendered":"<p><a href=\"https:\/\/news.google.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?oc=5\" target=\"_blank\">Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer<\/a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace<\/font><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Receives Positive EU CHMP Opinion for KEYTRUDA\u00ae (pembrolizumab) Plus Padcev\u00ae (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer&nbsp;&nbsp;BioSpace<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68],"tags":[],"class_list":["post-102986","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/102986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/comments?post=102986"}],"version-history":[{"count":0,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/posts\/102986\/revisions"}],"wp:attachment":[{"href":"https:\/\/flamenet.io\/api\/wp\/v2\/media?parent=102986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/categories?post=102986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flamenet.io\/api\/wp\/v2\/tags?post=102986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}